Silicon Valley’s Stanford University has teamed up with transplant diagnostic venture to sue genetic testing company Natera for patent infringement. The stakes are big. The litigation centers on cell-free DNA testing (cfDNA)—involves blood tests that enable physicians to understand what’s happening in someone’s body.
CareDX was founded 19 years ago. Nestled adjacent to a hillside just south of San Francisco, they have filed recent lawsuits that two of its patents give it exclusive right to non-invasively diagnose graft rejection in a wide array of organ transplants via cfDNA testing. These patents were owned by Stanford but licensed to CareDX according to TechCrunch. Follow the link to read the entire article.